There is also a wealth of preclinical evidence that CDK4/6 inhibitors display broad activity against a wide range of other tumour types (for reviews see (Asghar et al, 2015; O'Leary et al, 2016; Du et al, 2020)). This evidence concerns the gene CDK4 and neoplasm.